Literature DB >> 11126202

Brain expression of presenilins in sporadic and early-onset, familial Alzheimer's disease.

P M Mathews1, A M Cataldo, B H Kao, A G Rudnicki, X Qin, J L Yang, Y Jiang, M Picciano, C Hulette, C F Lippa, T D Bird, D Nochlin, J Walter, C Haass, L Lévesque, P E Fraser, A Andreadis, R A Nixon.   

Abstract

BACKGROUND: Mutations in the presenilin proteins cause early-onset, familial Alzheimer's disease (FAD).
MATERIALS AND METHODS: We characterized the cellular localization and endoproteolysis of presenilin 2 (PS2) and presenilin 1 (PS1) in brains from 25 individuals with presenilin-mutations causing FAD, as well as neurologically normal individuals and individuals with sporadic Alzheimer's disease (AD).
RESULTS: Amino-terminal antibodies to both presenilins predominantly decorated large neurons. Regional differences between the broad distributions of the two presenilins were greatest in the cerebellum, where most Purkinje cells showed high levels of only PS2 immunoreactivity. PS2 endoproteolysis in brain yielded multiple amino-terminal fragments similar in size to the PS1 amino-terminal fragments detected in brain. In addition, two different PS2 amino-terminal antibodies also detected a prominent 42 kDa band that may represent a novel PS2 form in human brain. Similar to PS1 findings, neither amino-terminal nor antiloop PS2 antibodies revealed substantial full-length PS2 in brain. Immunocytochemical examination of brains from individuals with the N141I PS2 mutation or eight different PS1 mutations, spanning the molecule from the second transmembrane domain to the large cytoplasmic loop domain, revealed immunodecoration of no senile plaques and only neurofibrillary tangles in the M139I PS1 mutation stained with PS1 antibodies.
CONCLUSIONS: Overall presenilin expression and the relative abundance of full-length and amino-terminal fragments in presenilin FAD cases were similar to control cases and sporadic AD cases. Thus, accumulation of full-length protein or other gross mismetabolism of neither PS2 nor PS1 is a consequence of the FAD mutations examined.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11126202      PMCID: PMC1949913     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  15 in total

1.  Immunization targeting a minor plaque constituent clears β-amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model.

Authors:  Jose Morales-Corraliza; Stephen D Schmidt; Matthew J Mazzella; Jason D Berger; Donald A Wilson; Daniel W Wesson; Mathias Jucker; Efrat Levy; Ralph A Nixon; Paul M Mathews
Journal:  Neurobiol Aging       Date:  2012-05-18       Impact factor: 4.673

2.  Protein levels of ADAM10, BACE1, and PSEN1 in platelets and leukocytes of Alzheimer's disease patients.

Authors:  Jessyka Maria de França Bram; Leda Leme Talib; Helena Passarelli Giroud Joaquim; Tamires Alves Sarno; Wagner Farid Gattaz; Orestes Vicente Forlenza
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-05-29       Impact factor: 5.270

3.  Chronic anti-murine Aβ immunization preserves odor guided behaviors in an Alzheimer's β-amyloidosis model.

Authors:  Daniel W Wesson; Jose Morales-Corraliza; Matthew J Mazzella; Donald A Wilson; Paul M Mathews
Journal:  Behav Brain Res       Date:  2012-09-20       Impact factor: 3.332

4.  γ-secretase binding sites in aged and Alzheimer's disease human cerebrum: the choroid plexus as a putative origin of CSF Aβ.

Authors:  Fei Liu; Zhi-Qin Xue; Si-Hao Deng; Xiong Kun; Xue-Gang Luo; Peter R Patrylo; Gregory M Rose; Huaibin Cai; Robert G Struble; Yan Cai; Xiao-Xin Yan
Journal:  Eur J Neurosci       Date:  2013-02-22       Impact factor: 3.386

5.  BRI2 protein regulates β-amyloid degradation by increasing levels of secreted insulin-degrading enzyme (IDE).

Authors:  Ellen Kilger; Anika Buehler; Heidrun Woelfing; Sathish Kumar; Stephan A Kaeser; Amudha Nagarathinam; Jochen Walter; Mathias Jucker; Janaky Coomaraswamy
Journal:  J Biol Chem       Date:  2011-08-26       Impact factor: 5.157

6.  Familial Alzheimer's disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta.

Authors:  Charles Arber; Jamie Toombs; Henrik Zetterberg; Selina Wray; Christopher Lovejoy; Natalie S Ryan; Ross W Paterson; Nanet Willumsen; Eleni Gkanatsiou; Erik Portelius; Kaj Blennow; Amanda Heslegrave; Jonathan M Schott; John Hardy; Tammaryn Lashley; Nick C Fox
Journal:  Mol Psychiatry       Date:  2019-04-12       Impact factor: 15.992

7.  Mild cognitive impairment and structural brain abnormalities in a sexagenarian with a history of childhood traumatic brain injury.

Authors:  John Darrell Van Horn; Andrei Irimia; Carinna M Torgerson; Avnish Bhattrai; Zachary Jacokes; Paul M Vespa
Journal:  J Neurosci Res       Date:  2017-05-20       Impact factor: 4.164

8.  Presenilin 1 interacts with acetylcholinesterase and alters its enzymatic activity and glycosylation.

Authors:  María-Ximena Silveyra; Geneviève Evin; María-Fernanda Montenegro; Cecilio J Vidal; Salvador Martínez; Janetta G Culvenor; Javier Sáez-Valero
Journal:  Mol Cell Biol       Date:  2008-02-25       Impact factor: 4.272

9.  Impact of aging: sporadic, and genetic risk factors on vulnerability to apoptosis in Alzheimer's disease.

Authors:  Katharina Schindowski; Tilmann Kratzsch; Jürgen Peters; Barbara Steiner; Silke Leutner; Natalie Touchet; Konrad Maurer; Christian Czech; Laurent Pradier; Lutz Frölich; Walter E Müller; Anne Eckert
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 3.843

10.  Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities.

Authors:  Lee-Way Jin; Feng-Shium Shie; Izumi Maezawa; Inez Vincent; Thomas Bird
Journal:  Am J Pathol       Date:  2004-03       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.